Loading...
Loading...
Keryx Biopharmaceuticals
KERX shares climbed 6.4% to $4.17 following announcement of the EU approval for Fexericx for the treatment of hyperphosphatemia in adults with chronic kidney disease. Share volume was 334,000, compared to an all-day average of 443,000
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
